The CSL Limited (ASX:CSL) share price rose 2% after the AstraZeneca – Oxford University COVID-19 vaccine was approved in Australia.
The post AstraZeneca vaccine approved for use in Australia, CSL (ASX:CSL) share price up appeared first on The Motley Fool Australia. –
According to reporting by the Australian Financial Review, the provisional approval will mean that adults who are 18 or older will be able to take two doses of the drug, between four to twelve weeks apart.
The Australian federal government has ordered almost 54 million doses of the vaccine, with CSL to start manufacturing within the country from the end of next month. CSL has been tasked with manufacturing 50 million doses.
One of the main benefits of the Oxford University – AstraZeneca COVID-19 vaccine is that it can be held in normal refrigerators. The Pfizer COVID-19 vaccine needs to be stored at -70C.
Some of the first Australians to receive the vaccine will be border workers, health workers involved in the fight against COVID-19, and people who are involved in aged care settings.
What is CSL’s involvement in the COVID-19 vaccine?
In regards to the COVID-19 vaccine, CSL announced back in September 2020 that it had signed an agreement with the Australian federal government.
CSL will manufacture the COVID-19 vaccine from its Australian facilities, as well as manufacturing the company’s vital core therapies.
The Australian government has provided funding to support CSL’s readiness to manufacture the Oxford University – AstraZeneca vaccine, which has expanded Australia’s on-shore vaccine manufacturing capabilities.
The funding is being used to establish at-risk components required to produce the commercial manufacture of the recombinant vector-based COVID-19 vaccine, including funding for specialised equipment, recruitment training and redeployment of personnel and retooling and reconfiguration of existing manufacturing facilities to ‘good manufacturing practice’ standards.
At the time of the announcement of the deal with the federal government, CSL CEO and managing director Paul Perreault said:
“Acknowledging that CSL is the only company in Australia with manufacturing facilities capable of producing this vaccine, we thank the Australian government for their support, ensuring Australia has access to onshore COVID-19 vaccine production and supply. Our facilities will require modifications in order to fulfil the compliance requirements for working with vector-based vaccines, as well as the addition of skilled personnel and further capital investment.”
Mr Perreault also spoke of the company’s prior involvement in manufacturing vaccines: “CSL’s history is linked with a commitment to Australia’s public health needs. In 1918 we produced a vaccine for the Spanish influenza pandemic, in 2009 we developed a vaccine for the swine flu pandemic, and now we are incredibly proud to use our skills, technology and facilities to help ensure Australia – and the world – can access a COVID-19 vaccine.”
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- ASX 200 Weekly Wrap: ASX cools on earnings reality check
- 5 things to watch on the ASX 200 next week
- How to generate $50,000 a year from ASX dividends
- Here’s how to make a $1 million share portfolio by investing $1,000 a month
- Top brokers name 3 ASX shares to buy today
Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post AstraZeneca vaccine approved for use in Australia, CSL (ASX:CSL) share price up appeared first on The Motley Fool Australia.